US 12,435,342 B2
Methods of packaging multiple adeno-associated virus vectors
Barry John Byrne, Gainesville, FL (US); Phillip A. Doerfler, Gainesville, FL (US); and Nathalie Clement, Gainesville, FL (US)
Assigned to University of Florida Research Foundation, Incorporated, Gainesville, FL (US)
Filed by University of Florida Research Foundation, Incorporated, Gainesville, FL (US)
Filed on Nov. 28, 2022, as Appl. No. 18/059,269.
Application 18/059,269 is a continuation of application No. 16/989,857, filed on Aug. 10, 2020, granted, now 11,535,867.
Application 16/989,857 is a continuation of application No. 15/320,707, granted, now 10,781,459, previously published as PCT/US2015/036841, filed on Jun. 20, 2015.
Claims priority of provisional application 62/015,031, filed on Jun. 20, 2014.
Prior Publication US 2023/0313230 A1, Oct. 5, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 21/02 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); C12Q 1/70 (2006.01)
CPC C12N 15/86 (2013.01) [C12N 7/00 (2013.01); C12Q 1/701 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14152 (2013.01); C12Q 2600/158 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A producer cell preparation for producing one or more recombinant adeno-associated virus particles, the producer cell preparation comprising:
a first nucleic acid vector containing a first construct, the first construct comprising a heterologous nucleic acid region encoding a first protein or polypeptide, and
a second nucleic acid vector containing a second construct, the second construct comprising a heterologous nucleic acid region encoding a second protein or polypeptide, wherein the first nucleic acid vector and the second nucleic acid vector are present at an initial ratio,
wherein the producer cell preparation is configured to produce a particle preparation comprising:
a first rAAV particle comprising the first construct, and
a second rAAV particle comprising the second construct, wherein the particle preparation comprises a target ratio of the first rAAV particle to the second rAAV particle within 15% of the initial ratio of the first nucleic acid vector to the second nucleic acid vector.